Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

SLRN

Acelyrin Inc

Dollar change +0.04
Percentage change 1.62	%

Apr 01 • 04:00PM ET

2.51

+0.041.62%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN MRNA BIIB AMGN ALNY GILD INCY BMRN NBIX

| Held by: VTI IWM VXF IWN IBB VTWO SCHA VHT IWC AVSC

Index	RUT	P/E	-	EPS (ttm)	-2.50	Insider Own	27.51%	Shs Outstand	100.45M	Perf Week	0.00%
Market Cap	252.78M	Forward P/E	-	EPS next Y	-1.67	Insider Trans	-0.09%	Shs Float	73.01M	Perf Month	-6.69%
Income	-248.23M	PEG	-	EPS next Q	-0.72	Inst Own	76.07%	Short Float	6.42%	Perf Quarter	-22.77%
Sales	0.00M	P/S	-	EPS this Y	22.82%	Inst Trans	5.50%	Short Ratio	2.11	Perf Half Y	-49.09%
Book/sh	4.56	P/B	0.55	EPS next Y	16.78%	ROA	-40.24%	Short Interest	4.68M	Perf Year	-62.81%
Cash/sh	4.45	P/C	0.56	EPS next 5Y	-	ROE	-44.54%	52W Range	1.85 - 7.25	Perf YTD	-20.06%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-53.43%	52W High	-65.38%	Beta	1.14
Dividend TTM	-	Quick Ratio	18.10	Sales past 5Y	0.00%	Gross Margin	-	52W Low	36.04%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	18.10	EPS Y/Y TTM	36.27%	Oper. Margin	-	RSI (14)	46.11	Volatility	5.03% 5.23%
Employees	83	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	8.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	18.77%	Payout	-	Rel Volume	0.23	Prev Close	2.47
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Mar 27	Avg Volume	2.22M	Price	2.51
SMA20	-5.52%	SMA50	6.44%	SMA200	-39.56%	Trades		Volume	519,619	Change	1.62%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-24	Downgrade	H.C. Wainwright	Buy → Neutral	$18 → $6
Jul-08-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$13
Dec-13-23	Initiated	Wells Fargo	Equal Weight	$11
Dec-08-23	Initiated	Citigroup	Neutral	$8
Sep-13-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Sep-05-23	Initiated	H.C. Wainwright	Buy	$44
May-30-23	Initiated	TD Cowen	Outperform
May-30-23	Initiated	Piper Sandler	Overweight	$68
May-30-23	Initiated	Morgan Stanley	Overweight
May-30-23	Initiated	Jefferies	Buy	$31

Mar-18-25 04:46AM	Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now (Insider Monkey)
Mar-14-25 07:57AM	Makary advances to full senate vote; Acelyrin, Pliant adopt poison pills (BioPharma Dive)
Mar-13-25 07:00AM	ACELYRIN Adopts Limited-Duration Stockholder Rights Plan (GlobeNewswire)
Mar-07-25 09:57AM	Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now? (Insider Monkey)
Mar-04-25 09:01AM	Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire) -7.06%
09:01AM	Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
09:01AM	ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:00AM	ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger (GlobeNewswire)
06:25AM	Neumora bids farewell to R&D head; Biohavens one step forward, one step back data (BioPharma Dive)
Feb-21-25 06:24AM	Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMAs new chair (BioPharma Dive) +19.82%
Feb-20-25 09:00PM	ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences (GlobeNewswire)
Feb-06-25 04:15PM	Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire) +7.37%
Jan-06-25 04:00PM	ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease (GlobeNewswire) -8.64% -36.96%
Jan-02-25 08:00PM	ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab (GlobeNewswire) +5.10% +15.76%
Dec-10-24 04:30PM	ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis (GlobeNewswire) -5.36% -16.01%
Nov-14-24 02:17AM	Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ... (GuruFocus.com) -13.71%
04:00PM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Nov-13-24 04:00PM	ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Nov-06-24 04:00PM	ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024 (GlobeNewswire)
Oct-16-24 07:00AM	ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease (GlobeNewswire) +6.29%
Sep-19-24 07:00AM	ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 (GlobeNewswire) +15.22%
Sep-12-24 01:30AM	Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc (GuruFocus.com)
Sep-10-24 07:00AM	ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery (GlobeNewswire)
Aug-22-24 07:00AM	ACELYRIN, INC. to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.42%
Aug-13-24 04:00PM	ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results (GlobeNewswire) -14.71%
03:37AM	Why Is Acelyrin, Inc. (SLRN) The Best New Penny Stock to Buy Now? (Insider Monkey)
Aug-06-24 04:30PM	ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024 (GlobeNewswire)
Jun-05-24 07:00AM	ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024 (GlobeNewswire)
May-29-24 07:00AM	ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024 (GlobeNewswire)
May-15-24 11:54AM	SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024 (InvestorPlace)
May-09-24 08:01AM	ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones (GlobeNewswire)
08:00AM	ACELYRIN, INC. Announces Leadership Transition (GlobeNewswire)
04:05PM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Apr-29-24 04:05PM	ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 (GlobeNewswire)
Mar-28-24 10:53PM	SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-27-24 04:01PM	Avalo Acquires Anti-IL-1 mAb and Announces Private Placement Financing of up to $185 Million (GlobeNewswire)
Mar-21-24 11:12AM	ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study (Zacks) -6.49%
Mar-20-24 07:00AM	ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease (GlobeNewswire)
12:39AM	Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen (FierceBiotech.com)
Mar-11-24 10:04AM	After crushing loss last year, Acelyrin rebounds with psoriatic arthritis victory (FierceBiotech.com) +10.96%
08:02AM	ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis (GlobeNewswire)
08:00AM	ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients (GlobeNewswire)
Feb-15-24 04:05PM	ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications (GlobeNewswire) +10.89%
Jan-10-24 11:30AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire) -5.08%
Jan-04-24 09:56AM	Final Deadline Approaching for Acelyrin, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of January 16, 2024 Lead Plaintiff Deadline (GlobeNewswire)
Jan-01-24 09:35AM	Acelyrin (SLRN) Faces Investor Fraud Lawsuit for Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Dec-27-23 10:45AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Dec-20-23 04:30PM	ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors (GlobeNewswire) -5.94%
Dec-19-23 12:13AM	Robbins LLP Reminds Investors of Lawsuit Against Acelyrin, Inc. and Approaching Lead Plaintiff Deadline (GlobeNewswire)
Dec-18-23 04:14PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire) -7.49%
Dec-12-23 09:25PM	ACELYRIN, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2024 deadline (GlobeNewswire) +8.51%
Dec-11-23 09:35AM	SLRN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire) -7.47%
Dec-04-23 03:00PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress - Hagens Berman (GlobeNewswire)
08:00AM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
Nov-30-23 04:30PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire) +5.66%
Nov-28-23 05:55PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2023 deadline (GlobeNewswire) -32.41% +8.16%
01:44PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
07:24AM	5 Things to Know Before Markets Open (Investopedia)
Nov-27-23 09:09PM	Acelyrin blames CRO error for shocking phase 3 failure that sent shiver through biotech IPO market (FierceBiotech.com)
04:30PM	ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program (GlobeNewswire)
Nov-20-23 11:01AM	Acelyrin (SLRN) Faces Lawsuit after Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Nov-16-23 06:42PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
04:11PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Nov-07-23 05:11PM	Acelyrin Inc (SLRN) Reports Q3 2023 Financial Results: Key Clinical Trials Progressing (GuruFocus.com) -8.70%
04:05PM	ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Nov-06-23 07:00AM	ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer (GlobeNewswire)
Oct-31-23 04:30PM	ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023 (GlobeNewswire) -10.36%
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Acelyrin, and Clorox and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-03-23 07:00AM	ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development (GlobeNewswire)
Sep-15-23 05:39PM	Why Acelyrin Stock Plummeted 59% This Week (Motley Fool)
Sep-11-23 04:05PM	ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa (GlobeNewswire) -54.12%
Sep-06-23 07:00AM	ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-23 07:22PM	Billionaire Ken Griffin Pours Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks) +7.70%
Aug-14-23 04:05PM	ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Aug-07-23 04:30PM	ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023 (GlobeNewswire)
Jul-18-23 07:00AM	ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer (GlobeNewswire)
Jun-15-23 04:05PM	ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-09-23 04:10PM	ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
May-05-23 07:08PM	Drug Developer Acelyrin Raises $540 Million in IPO (The Wall Street Journal)

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Institutional Ownership

T. Rowe Price Investment Management, Inc.	12.83%
AyurMaya Capital Management Company, LP	9.30%
BlackRock, Inc.	6.00%
MILLENNIUM MANAGEMENT LLC	4.70%
CITADEL ADVISORS LLC	4.20%
VANGUARD GROUP INC	4.07%
ORBIMED ADVISORS LLC	3.99%
venBio Partners LLC	3.79%
TYBOURNE CAPITAL MANAGEMENT	2.90%
Blue Owl Capital Holdings LP	2.77%

Insider Trading Volume

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kim Mina	Chief Executive Officer	Mar 17 '25	Sale	2.74	17,986	49,354	671,753	Mar 19 06:11 PM
Murugan Amar	Chief Legal Officer	Mar 17 '25	Sale	2.74	3,913	10,737	121,587	Mar 19 06:06 PM
Mpofu Shephard	Chief Medical Officer	Mar 17 '25	Sale	2.74	3,211	8,811	121,789	Mar 19 05:55 PM
Kim Mina	Officer	Mar 17 '25	Proposed Sale	2.75	18,052	49,643		Mar 14 09:04 PM
Becker Daniel J.	Director	Jul 17 '24	Sale	6.86	1	7	2,999	Jul 19 06:18 PM

Dollar change +0.07
Percentage change 1.18	%

ATRA Atara Biotherapeutics Inc daily Stock Chart

Peers: GILD NVS ALLO BLUE FATE EDIT CLLS ADAP CARA IMMP

| Held by: VTI VXF BTEC

Index	-	P/E	-	EPS (ttm)	-12.87	Insider Own	35.17%	Shs Outstand	5.86M	Perf Week	-13.15%
Market Cap	35.21M	Forward P/E	-	EPS next Y	-2.10	Insider Trans	-0.47%	Shs Float	3.80M	Perf Month	-14.14%
Income	-85.40M	PEG	-	EPS next Q	-2.33	Inst Own	40.45%	Short Float	19.03%	Perf Quarter	-50.53%
Sales	128.94M	P/S	0.27	EPS this Y	58.60%	Inst Trans	22.94%	Short Ratio	3.58	Perf Half Y	-25.57%
Book/sh	-16.60	P/B	-	EPS next Y	55.55%	ROA	-62.20%	Short Interest	0.72M	Perf Year	-65.36%
Cash/sh	7.28	P/C	0.83	EPS next 5Y	30.84%	ROE	-	52W Range	5.40 - 20.81	Perf YTD	-54.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.00%	ROI	-	52W High	-71.12%	Beta	0.32
Dividend TTM	-	Quick Ratio	0.40	Sales past 5Y	306.01%	Gross Margin	83.71%	52W Low	11.30%	ATR (14)	0.58
Dividend Ex-Date	-	Current Ratio	0.48	EPS Y/Y TTM	59.49%	Oper. Margin	-60.75%	RSI (14)	36.60	Volatility	6.84% 8.14%
Employees	153	Debt/Eq	-	Sales Y/Y TTM	1404.02%	Profit Margin	-66.23%	Recom	1.86	Target Price	11.20
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	91.50%	Payout	-	Rel Volume	0.38	Prev Close	5.94
Sales Surprise	59.12%	EPS Surprise	58.41%	Sales Q/Q	670.30%	Earnings	Mar 07 AMC	Avg Volume	202.10K	Price	6.01
SMA20	-11.15%	SMA50	-20.14%	SMA200	-35.23%	Trades		Volume	76,058	Change	1.18%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-09-23	Downgrade	Mizuho	Buy → Neutral	$31 → $1
Nov-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Downgrade	Citigroup	Neutral → Sell	$8 → $3
Jul-13-22	Downgrade	Stifel	Buy → Hold	$16 → $5
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral	$10
May-10-22	Downgrade	Citigroup	Buy → Neutral	$15 → $8
May-13-21	Upgrade	JP Morgan	Neutral → Overweight	$23 → $29
Dec-09-20	Downgrade	Citigroup	Buy → Neutral	$20 → $27
Dec-08-20	Reiterated	H.C. Wainwright	Buy	$28 → $31
Nov-10-20	Reiterated	H.C. Wainwright	Buy	$26 → $28
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy	$25
Apr-23-20	Upgrade	Citigroup	Neutral → Buy	$14
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral	$43 → $22
Sep-27-19	Downgrade	Goldman	Neutral → Sell	$14 → $9
Sep-16-19	Downgrade	Jefferies	Buy → Hold	$32 → $15
Jun-04-19	Upgrade	Citigroup	Sell → Neutral	$23 → $24
May-30-19	Initiated	ROTH Capital	Buy
May-23-19	Initiated	Stifel	Buy

Show Previous Ratings

Mar-13-25 12:00PM	Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Mar-07-25 05:10PM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -10.72%
04:16PM	Atara Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress (Business Wire)
Feb-14-25 09:55AM	Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet (Zacks)
08:11AM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
08:11AM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws (PR Newswire)
Feb-07-25 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.95%
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive) +13.88%
Jan-21-25 01:11PM	FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs (Benzinga) -7.91%
07:30AM	Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO (tabelecleucel) and ATA3219 (Business Wire)
Jan-17-25 07:00AM	Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs (BioPharma Dive) -16.09%
Jan-16-25 12:28PM	Atara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO Application (GuruFocus.com) -40.50%
08:30AM	Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel) (Business Wire)
Jan-02-25 12:00PM	Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why (Zacks) +6.39%
Dec-04-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
07:00AM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Dec-03-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Nov-27-24 04:01PM	Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-24 04:01PM	Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference (Business Wire) +22.19% -10.45%
Nov-12-24 05:15PM	Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:13PM	Atara Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress (Business Wire)
Nov-05-24 04:01PM	Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (Business Wire) -11.61%
Oct-15-24 12:00PM	Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know (Zacks)
Oct-04-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.81%
Sep-30-24 03:16AM	After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? (Pharma Voice)
Sep-13-24 07:02PM	Redmile Group, LLC Expands Stake in Atara Biotherapeutics Inc (GuruFocus.com) +20.30% -11.52%
Sep-06-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.30% -5.28%
Sep-04-24 04:01PM	Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) +32.89% +10.50%
Sep-03-24 04:16PM	Atara Biotherapeutics Announces $36 Million Registered Direct Offering (Business Wire) -10.39%
Aug-12-24 06:10PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
05:07PM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
05:07PM	Atara Biotherapeutics: Q2 Earnings Snapshot (Associated Press Finance)
05:00PM	Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update (Business Wire)
Aug-07-24 04:01PM	Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire) -9.79%
Jul-19-24 06:12AM	US FDA grants priority review for Pierre Fabres EBV+ PTLD (Pharmaceutical Technology)
Jul-17-24 04:13PM	FDA priority review advances Ataras tabelecleucel for viral infection (Pharmaceutical Technology) -12.82%
09:00AM	Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Business Wire)
07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire) +9.95%
Jul-15-24 12:00PM	All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy (Zacks) +6.59%
Jul-05-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.39%
Jul-03-24 07:57PM	Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum (Business Wire)
Jun-21-24 04:01PM	Atara Biotherapeutics Ebvallo (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases (Business Wire) -7.53%
Jun-17-24 08:00AM	Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split (Business Wire) -16.93%
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire) +7.68%
Jun-07-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.08%
Jun-05-24 04:01PM	Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-29-24 04:01PM	Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting (Business Wire) -8.42%
May-20-24 11:57AM	Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise (MT Newswires) +16.39%
09:25AM	Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA (Business Wire)
May-09-24 10:57PM	ATRA Stock Earnings: Atara Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:15PM	Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:17PM	Atara Biotherapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress (Business Wire)
May-03-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.00%
Apr-05-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-28-24 01:53PM	ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
09:40AM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:40AM	Atara Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance)
08:30AM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress (Business Wire)
Feb-29-24 09:05AM	Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy (Business Wire)
Feb-28-24 04:30PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference (Business Wire)
Feb-14-24 09:00AM	Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis (Business Wire)
Jan-31-24 06:30PM	Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel Data in The Lancet Oncology (Business Wire) +33.10%
Jan-11-24 01:26AM	Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding (GuruFocus.com) +5.31%
01:26AM	Seth Klarman's Exit from Atara Biotherapeutics Inc (GuruFocus.com)
Jan-08-24 09:00AM	Atara Biotherapeutics Announces $15 Million Registered Direct Offering (Business Wire) +25.28%
08:00AM	Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-04-24 04:01PM	Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-20-23 04:01PM	Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories (Business Wire) -19.44%
Dec-11-23 12:00PM	Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting (Business Wire)
Dec-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.10%
Nov-29-23 06:05PM	Atara Biotherapeutics To Present Positive New Tab-cel Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023 (Business Wire) +13.36%
Nov-24-23 12:29PM	Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why (Zacks) +13.93%
Nov-22-23 04:01PM	Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire) +13.22%
09:14AM	Billionaire Seth Klarmans Biotech Stock Picks (Insider Monkey)
Nov-10-23 04:01PM	Atara Biotherapeutics To Participate at the Stifel Healthcare Conference (Business Wire) +11.88%
Nov-09-23 08:23AM	Why Is Atara Biotherapeutics (ATRA) Stock Down 50% Today? (InvestorPlace) -80.17%
06:40AM	Ataras cell therapy approach to MS falls short in study (BioPharma Dive)
Nov-08-23 05:35PM	Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis (Business Wire) -9.02%
Nov-05-23 12:50PM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 05:42AM	Atara Biotherapeutics Inc (ATRA) Announces Q3 2023 Financial Results and Expanded Global Partnership (GuruFocus.com) -5.56%
02:25AM	Q3 2023 Atara Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 08:35AM	Atara Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:30AM	Atara Biotherapeutics Announces Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results (Business Wire)
Oct-06-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.09%
Sep-21-23 09:19AM	Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study (Zacks)
Sep-19-23 04:01PM	Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability (Business Wire) +11.39%
Sep-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.16%
Aug-31-23 04:01PM	Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference (Business Wire)
Aug-13-23 10:44AM	10 Most Promising Penny Stocks According to Analysts (Insider Monkey)
Aug-08-23 05:30PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -17.18%
04:18PM	Atara Biotherapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress (Business Wire)
Aug-04-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-23 04:01PM	Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (Business Wire)
Jul-31-23 04:01PM	Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire) +7.28%
Jul-29-23 11:07AM	10 Stocks That Will Go Up 1000 Percent (Insider Monkey)
Jul-17-23 07:29AM	3 Doomed Biotech Stocks Destined for Disaster (InvestorPlace) +6.56%
Jul-07-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.45% +5.41%

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Institutional Ownership

EcoR1 Capital, LLC	9.24%
Redmile Group, LLC	7.67%
CITADEL ADVISORS LLC	4.64%
BANK OF AMERICA CORP /DE/	3.56%
VANGUARD GROUP INC	3.10%
Vestal Point Capital, LP	2.17%
ACADIAN ASSET MANAGEMENT LLC	2.16%
TANG CAPITAL MANAGEMENT LLC	1.31%
RENAISSANCE TECHNOLOGIES LLC	1.17%
BlackRock, Inc.	1.06%

Insider Trading Volume

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nguyen AnhCo	President and CEO	Mar 03 '25	Sale	7.00	3,331	23,307	74,123	Mar 05 05:17 PM
Hyllengren Eric J	EVP, CFO and COO	Mar 03 '25	Sale	7.00	1,211	8,473	56,231	Mar 05 05:17 PM
Henrich Jill	EVP, Chief Regulatory Officer	Mar 03 '25	Sale	7.00	1,059	7,410	18,679	Mar 05 05:16 PM
Nguyen AnhCo	Officer	Mar 03 '25	Proposed Sale	6.91	3,929	27,149		Mar 03 06:30 PM
Hyllengren Eric J	Officer	Mar 03 '25	Proposed Sale	6.91	1,426	9,854		Mar 03 06:29 PM
Henrich Jill	Officer	Mar 03 '25	Proposed Sale	6.91	1,245	8,603		Mar 03 06:27 PM
Henrich Jill	EVP, Chief Regulatory Officer	Nov 18 '24	Sale	11.20	1,000	11,198	19,378	Nov 20 06:05 PM
Hyllengren Eric J	EVP, CFO and COO	Nov 18 '24	Sale	11.20	1,364	15,274	23,392	Nov 20 06:04 PM
Nguyen AnhCo	President and CEO	Nov 18 '24	Sale	11.20	1,664	18,633	77,454	Nov 20 06:04 PM
Nguyen AnhCo	Officer	Nov 18 '24	Proposed Sale	12.00	1,857	22,284		Nov 18 05:58 PM
Murugan Amar	Former Officer	Nov 18 '24	Proposed Sale	12.00	1,342	16,104		Nov 18 05:56 PM
Hyllengren Eric J	Officer	Nov 18 '24	Proposed Sale	12.00	1,517	18,204		Nov 18 05:55 PM
Henrich Jill	Officer	Nov 18 '24	Proposed Sale	12.00	1,112	13,344		Nov 18 05:54 PM
Touchon Pascal	President and CEO	Aug 16 '24	Sale	6.63	3,038	20,139	70,127	Aug 20 06:27 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Aug 16 '24	Sale	6.63	1,821	12,072	34,118	Aug 20 06:27 PM
Murugan Amar	EVP, Chief Legal Officer	Aug 16 '24	Sale	6.63	1,158	7,677	26,827	Aug 20 06:27 PM
Hyllengren Eric J	EVP, CFO	Aug 16 '24	Sale	6.63	1,070	7,093	24,756	Aug 20 06:27 PM
Henrich Jill	EVP, Global Head RA & Quality	Aug 16 '24	Sale	6.63	963	6,384	20,378	Aug 20 06:26 PM
Touchon Pascal	Director	Aug 16 '24	Proposed Sale	8.02	3,525	28,270		Aug 16 04:12 PM
Nguyen AnhCo	Officer	Aug 16 '24	Proposed Sale	8.02	2,114	16,954		Aug 16 04:10 PM
Murugan Amar	Officer	Aug 16 '24	Proposed Sale	8.02	1,342	10,763		Aug 16 04:09 PM
Hyllengren Eric J	Officer	Aug 16 '24	Proposed Sale	8.02	1,239	9,937		Aug 16 04:08 PM
Henrich Jill	Officer	Aug 16 '24	Proposed Sale	8.02	1,113	8,926		Aug 16 04:06 PM
Touchon Pascal	President and CEO	May 16 '24	Sale	0.62	81,506	50,289	1,829,146	May 20 08:34 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	May 16 '24	Sale	0.62	42,899	26,469	898,498	May 20 08:34 PM
Murugan Amar	EVP, Chief Legal Officer	May 16 '24	Sale	0.62	32,401	19,991	695,120	May 20 08:33 PM
Hyllengren Eric J	EVP, CFO	May 16 '24	Sale	0.62	28,648	17,676	645,671	May 20 08:33 PM
Henrich Jill	EVP, Global Head RA & Quality	May 16 '24	Sale	0.62	25,750	15,888	529,251	May 20 08:32 PM

SLRN

Acelyrin Inc

Institutional Ownership

ATRA

Atara Biotherapeutics Inc

Institutional Ownership

Upgrade your FINVIZ experience